CYNATA THERAPEUTICS LIMITED

6.45%

16.5¢

Market Cap $37.28M

Healthcare Biotechnology

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and... Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) accelerates commercialisation with positive Phase II results.

Latest Threads

Tag

Subject

CYP

"Good vibes Here Dudes".....

2 3

31/07/25

146

49K

31/07/25

Last post Kerebrad

146

49K

CYP

Ann: June 2025 Quarterly Activity Report and Appendix 4C

31/07/25

953

31/07/25

Last post Pledge

953

CYP

Ann: CYP-001s FDA Approval Pathway Not Impeded

2 3

30/07/25

127

25K

30/07/25

Last post Pledge

127

25K

CYP Biotech

CYP Price Target post MSB FDA approval.

5 6 7

28/07/25

380

111K

28/07/25

Last post bedger

380

111K

CYP

Paving the way for next-gen treatments

19/07/25

6.0K

19/07/25

Last post Rossi70

6.0K

CYP

Ann: Recruitment Completed in Phase 3 OA Clinical Trial

04/07/25

13K

04/07/25

Last post Pledge

13K

CYP

Ann: Proposed issue of securities - CYP

20/06/25

11K

20/06/25

Last post gavint66

11K

CYP

Moving North

19/06/25

13K

19/06/25

Last post Pledge

13K

See All Discussions

Timeline

June 2025 Quarterly Activity Report and Appendix 4C
30 Jul 09:45	Share

Notification regarding unquoted securities - CYP
10 Jun 15:57	Share

Proposed issue of securities - CYP
04 Jun 08:24	Share

InvestorHub Portal and New Website
22 May 08:43	Share

CYP-001s FDA Approval Pathway Not Impeded
16 May 12:12	Share

Investor Webinar
05 May 08:28	Share

March 2025 Quarterly Activity Report and Appendix 4C
24 Apr 13:12	Share

Australian Federal Government Announces Funding of SMART CRC
24 Apr 11:48	Share

Cynata Establishes New Scientific Advisory Board
14 Apr 08:45	Share

Promising Preclinical Heart Disease Data
07 Apr 08:46	Share

Appendix 3Ys x 4
01 Apr 18:00	Share

Cynata Presenting at Advanced Therapies Congress
18 Mar 08:50	Share

Cynata Participating in Euroz Hartleys Investor Conference
12 Mar 08:53	Share

Appendix 4D & Half-Year Financial Statements
27 Feb 15:04	Share

Expiry of listed CYPOA Options
27 Feb 11:58	Share

Appendix 3Y - Paul Wotton
20 Feb 15:22	Share

Application for quotation of securities - CYP
20 Feb 15:17	Share

Investor Webinar
06 Feb 08:56	Share

Publication comparing Cymerus MSCs to other MSCs
05 Feb 09:12	Share

Cynata to Present at Euroz Hartleys Healthcare Forum
04 Feb 08:37	Share

Quarterly Activity Report & Appendix 4C
30 Jan 08:52	Share

Appendix 3Y x 5
23 Jan 15:44	Share

Cleansing Notice
23 Jan 15:38	Share

Application for quotation of securities - CYP
23 Jan 15:36	Share

Results of Meeting
21 Jan 12:41	Share

Cynata to Present at Biotech Showcase
13 Jan 09:24	Share

Change in substantial holding - Phillip Asset Management
31 Dec 13:36	Share

Letter to Shareholders, Notice of EGM & Proxy Form
20 Dec 12:44	Share

Cleansing Notice
16 Dec 09:26	Share

Application for quotation of securities - CYP
16 Dec 09:22	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 16.5¢		Change 0.010(6.45%)		Mkt cap ! $37.28M

Open	High	Low	Value	Volume
16.0¢	16.5¢	16.0¢	$5.061K	31.17K

Buyers (Bids)

No.	Vol.	Price($)
2	3451	16.0¢

Sellers (Offers)

Price($)	Vol.	No.
16.5¢	90000	1

View Market Depth

No.	Vol.	Price($)
2	3451	0.160
6	229789	0.155
7	403545	0.150
4	81775	0.145
4	29291	0.140

Price($)	Vol.	No.
0.165	90000	1
0.170	26942	1
0.175	52845	2
0.180	175059	7
0.185	34554	4

Last trade - 10.08am 01/08/2025 (20 minute delay)


Last 16.5¢		Change 0.010 ( 3.13 %)
Open	High	Low	Volume
16.5¢	16.5¢	16.5¢	375
Last updated 10.08am 01/08/2025 ?

CYP (ASX) Chart

CYNATA THERAPEUTICS LIMITED

Latest Threads

Redcastle Resources Delivers Positive Scoping Study for Queen Alexandra

Timeline

Featured News

Latest Videos

Cynata Therapeutics (ASX:CYP) receives approval for acute graft-versus-host disease clinical trial

30 Jan 2023 14:49 (AEDT)

Latest Articles

Cynata's stem cell tech verified in peer-reviewed study

Cynata Therapeutics (ASX:CYP) has had its induced pluripotent stem cell (iPSC) derived mesenchymal stem cell (MSCs) verified as similar to convention MSCs in a study published in a peer-review journal.

Cynata study shows efficacy of stem-cell therapy on chronic lung disease

Cynata Therapeutics Ltd has published a study examining the effect of its Cymerus therapy on idiopathic pulmonary fibrosis symptoms.

Cynata wins EU ethics approval for phase 2 Trial of CYP-001

Cynata Therapeutics has been given EU regulatory and ethics approval for phase 2 Trial of its latest development 'CYP-001'

Buyers (Bids)

Sellers (Offers)

Codeifai looks to ride AI wave as Quantum Computing becomes a necessity

Prospect Resources: Replicating the success of Arcadia with ~1b tonne copper ore target

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Resolution Minerals appoints industry experts to fast-track US growth strategy

Top Stories

Featured News